Citations (6)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Mangat Ram Dogra & Anand Vinekar. (2023) Role of Anti-Vascular Endothelial Growth Factor (Anti-VEGF) in the Treatment of Retinopathy of Prematurity: A Narrative Review in the Context of Middle-Income Countries. Pediatric Health, Medicine and Therapeutics 14, pages 59-69.
Read now
Read now
Mohammad Etezad Razavi, Nasser Shoeibi, Samira Hassanzadeh, Sedigheh Kianmehr & Elham Bakhtiari. (2020) Refractive outcome of intravitreal bevacizumab injection in comparison to spontaneous regression of retinopathy of prematurity (ROP). Strabismus 28:1, pages 49-54.
Read now
Read now
Articles from other publishers (4)
Chiharu Iwahashi, Tomoki Kurihara, Kazuki Kuniyoshi & Shunji Kusaka. (2023) Long-Term Visual Prognosis of Patients Following Lens-Sparing Vitrectomy for Stage 4A Retinopathy of Prematurity. International Journal of Molecular Sciences 24:3, pages 2416.
Crossref
Crossref
Ching-Yen Huang, Shen-Hao Lai, Hsiao-Jung Tseng, Tsung-Chieh Yao & Wei-Chi Wu. (2022) Pulmonary function in school-age children following intravitreal injection of bevacizumab for retinopathy of prematurity. Scientific Reports 12:1.
Crossref
Crossref
Domenico Lepore, Marco H. Ji, Graham E. Quinn, Giulia M. Amorelli, Lorenzo Orazi, Daniela Ricci & Eugenio Mercuri. (2020) Functional and Morphologic Findings at Four Years After Intravitreal Bevacizumab or Laser for Type 1 ROP. Ophthalmic Surgery, Lasers and Imaging Retina 51:3, pages 180-186.
Crossref
Crossref
T. U. Krohne, A. Müller, P. P. Larsen & F. G. Holz. (2018) Langzeiteffekte der Anti-VEGF-Therapie bei FrühgeborenenretinopathieLong-term effects of anti-VEGF therapy for retinopathy of prematurity. Der Ophthalmologe 115:6, pages 464-468.
Crossref
Crossref